Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Stephens

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cancers|February 11, 2023
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer MassesNirmala Chandralega Kampan, Apriliana Ellya Ratna Kartikasari, Cyril Deceneux, et al.
Proteomics. Clinical Applications|February 10, 2018
Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient UrineJarrod J Sandow, Adam Rainczuk, Giuseppe Infusini, et al.
Endocrinology|October 6, 2011
Proprotein convertase 5/6 is critical for embryo implantation in women: regulating receptivity by cleaving EBP50, modulating ezrin binding, and membrane-cytoskeletal interactionsSophea Heng, Ana Cervero, Carlos Simon, et al.
Genome Medicine|August 11, 2015
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Genome Medicine|January 14, 2017
Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Oncotarget|April 11, 2022
Role of the prorenin receptor in endometrial cancer cell growthJacinta H Martin, Riazuddin Mohammed, Sarah J Delforce, et al.
Oncotarget|October 28, 2015
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesSally M Hunter, Michael S Anglesio, Georgina L Ryland, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 30, 2020
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, Dane Cheasley, Cecile LePage, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cancers|February 11, 2023
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer MassesNirmala Chandralega Kampan, Apriliana Ellya Ratna Kartikasari, Cyril Deceneux, et al.
Proteomics. Clinical Applications|February 10, 2018
Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient UrineJarrod J Sandow, Adam Rainczuk, Giuseppe Infusini, et al.
Endocrinology|October 6, 2011
Proprotein convertase 5/6 is critical for embryo implantation in women: regulating receptivity by cleaving EBP50, modulating ezrin binding, and membrane-cytoskeletal interactionsSophea Heng, Ana Cervero, Carlos Simon, et al.
Genome Medicine|August 11, 2015
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Genome Medicine|January 14, 2017
Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Oncotarget|April 11, 2022
Role of the prorenin receptor in endometrial cancer cell growthJacinta H Martin, Riazuddin Mohammed, Sarah J Delforce, et al.
Oncotarget|October 28, 2015
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesSally M Hunter, Michael S Anglesio, Georgina L Ryland, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 30, 2020
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, Dane Cheasley, Cecile LePage, et al.
Pageof 7